News

Costa Ricans and IncellDx develop alternative for the clinical prognosis of COVID-19
June 24, 2021

IncellDx to Study Maraviroc, a CCR5 antagonist, in a COVID-19 Phase 2 Clinical Trial
October 19, 2020

IncellDx Awarded PD-L1 Detection and Quantification Paten in Tumor cells and CTCs 
September 24, 2020

IncellDx to Extend Precision Medicine Reach With Factorial Diagnostics Collaboration
August 13, 2020

IncellDx Signs Exclusive Deal with Factorial Diagnostics 
August 06, 2020

IncellDx Files Patent for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19 and Other Cytokine Storm Conditions
June 18, 2020

IncellDx’s Next Gen HPV/Cervical Cancer Assay (HPV OncoTect 3Dx) Receives Clinical Approval from Costa Rican Ministry of Health
June 10, 2020

U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn’s Leronlimab
March 19, 2020

IncellDx Signs Liquid Biopsy Distribution Agreement with Singapore-based Biolidics, Inc. 
December 18, 2019

IncellDx, Beckman Coulter Form Cancer Assay Promotion Agreement 
November 20, 2019

IncellDx Inks Chinese Collaboration, Distribution Agreements
August 5, 2019

Zomedica partners with IncellDx to help fight canine and human cancer
December 21, 2018

IncellDx and Zomedica Sign Diagnostic CTC Assay Development Agreement for Canine Cancer
December 19, 2018

Sirona Dx Launches Novel Urine-Based Bladder Cancer Assay with PD-L1 Quantification Based on IncellDx’s Single Cell Immuno-Oncology/PD-L1 Technology
October 30, 2018

IncellDx Launches BioINK and Lyophilized CTC Control Cells
August 17, 2018

IncellDx gets published in American Journal of Clinical Pathology,
“Concordance of PD-L1 Expression Detection in Non-Small Cell Lung Cancer (NSCLC) Tissue Biopsy Specimens Between OncoTect iO Lung Assay and Immunohistochemistry (IHC)”
July 24, 2018

IncellDx get CE mark for HPV Assay
May 21, 2018

BPI and IncellDx, Inc. Announce OEM and International Distribution Agreement for Single Cell Immuno-Oncology and Oncology Diagnostic Products in Middle East and North Africa (MENA)
May 10, 2018

CellMax Life and IncellDx Partner to Develop Blood Tests to De-Risk Clinical Trials Relying on Tissue-Based Biomarkers
April 10, 2018

Laboratorio Noy Launches Novel PD-L1 Assay for Bladder Cancer Based on IncellDx’s Single Cell Immuno-Oncology/PD-L1 Technology
February 07, 2018

Premas, IncellDx Ink India Distribution Agreement
January 17, 2018

IncellDx and Celsee Commercialize Assays After Cancer Study Collaboratio
January 11, 2018

IncellDx partners with GIMDx for distribution in China
October 19, 2017

IncellDx Releases CE-IVD Quantitative Single Cell PD-L1 OncoTect iO® Assay
March 30, 2017

IncellDx Launches OncoTect iO™ Quantitative, Single Cell PD-L1 Assay
March 07, 2017

IncellDx Partners with Celsee Diagnostics Announces Immuno-Oncology Research Agreement
February 14, 2017

IncellDx Gets IVD, CE-IVD Status for incellPREP Single Cell Suspension Kit 
January 6, 2017

IncellDx presents poster at IASLC 17th World Conference on Lung Cancer
December 5, 2016

IncellDx and Beckman Coulter Sign Distribution Partnership in China, Hong Kong and Taiwan to Benefit Human Papilloma Virus (HPV) Research
November 12, 2015

IncellDx presents poster at GLIFCA 2015 in Buffalo, NY.
September 27, 2015

IncellDx presents poster at IPV 2015 in Lisbon
September 21, 2015

IncellDx Stikes a partnership with Claremont-BioSolutions
April 14, 2015

MD Anderson and PPRI uses IncellDx’s OncoBreast3Dx® Technology.
January 27, 2015

Journal of Clinical Microbiology publishes New HIV article by IncellDx.
October 29, 2014

IncellDx Signs Agreement with Bristol-Myers Squibb Related to the Development of an Assay for a Companion Diagnostic Test
October 29, 2013

IncellDx Signs Deal with CureHealth Diagnostics to Offer New HPV Technology in India
June 21, 2013

IncellDx Signs Deal with Kindstar Global to Offer Novel HPV Technology in China
June 11, 2013

IncellDx Presents First Study Using Their Novel OncoBreast 3Dx™ Breast Cancer Technology
January 8, 2013

IncellDx Receives North American Product Leadership Award in the Molecular Diagnostics Market from Frost & Sullivan
July 19, 2012

BRLI Announces IncellDx Investment and Launch of GenCerv Test Through Its GenPath Women’s Health Laboratory
April 30, 2012

IncellDx Announces the Expansion of HPV OncoTect® E6, E7 mRNA by Labco Laboratories Throughout Europe
February 8, 2012

IncellDx CEO applauds new cervical cancer screening recommendations- Technology identifies cancer with more certainty than current tests
October 21, 2011

Enzo Biochem Reaches Marketing Deal for IncellDx’s HPV Test
June 10, 2011

IncellDx Unveils Revolutionary New Technology In The Fight Against Cancer
May 10, 2011

IncellDx Announces New Director of Research and Development
March 17, 2011

IncellDx, Inc. Receives ISO 13485:2003 and ISO 9001:2008 Certifications
March 3, 2011

IncellDx Biotech Company of the Year
December 2, 2010

IncellDx Announces Successful Presentation of its Personalized HIV Monitoring Assays at the 5th Santorini Conference in Greece
October 5, 2010

IncellDx Announces Successful Presentation of Complete Solution for Cervical Cancer Screening at International HPV Conference in Montreal
July 9, 2010

IncellDx Secures $3 Million in Series A Financing
June 8, 2010

IncellDx Announces Expansion Of Senior Management Team
May 19, 2010

IncellDx Announces a Supply Agreement with Accuri to Offer Complete Solution for Cervical Cancer Screening
May 6, 2010

Silicon Venture Personalized Medicine Presentation
January 19, 2010